Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
7.46
+0.08 (1.08%)
At close: Feb 21, 2025, 4:00 PM
7.49
+0.03 (0.40%)
After-hours: Feb 21, 2025, 4:38 PM EST
Nutriband Revenue
Nutriband had revenue of $645.80K in the quarter ending October 31, 2024, with 50.94% growth. This brings the company's revenue in the last twelve months to $2.02M, down -3.18% year-over-year. In the fiscal year ending January 31, 2024, Nutriband had annual revenue of $2.09M with 0.27% growth.
Revenue (ttm)
$2.02M
Revenue Growth
-3.18%
P/S Ratio
36.57
Revenue / Employee
$155,521
Employees
13
Market Cap
82.85M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NTRB News
- 1 day ago - Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development. - GlobeNewsWire
- 9 days ago - Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch - GlobeNewsWire
- 15 days ago - Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™ - GlobeNewsWire
- 7 weeks ago - Nutriband Issues Letter to Shareholders - GlobeNewsWire
- 2 months ago - Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology - GlobeNewsWire
- 2 months ago - Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025 - GlobeNewsWire
- 3 months ago - Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology - GlobeNewsWire
- 4 months ago - Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application - Accesswire